CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis

Yang

J of Periodontal Research

et al. 2018

We conclude that EMMPRIN glycosylation participates in the regulation of MMP-2 and MMP-9 production through mediating the interaction of HIOECs and HGFs. Inhibiting EMMPRIN glycosylation can reduce the activation of MMP-2 and MMP-9 and suppress the degradation of extracellular matrix (ECM) in the HIOEC/HGF co-culture model. Therefore, this study suggests that EMMPRIN glycosylation may affect the host immune-inflammatory response by regulating MMPs in periodontitis.

Section: Discussionmentioning

confidence: 99%

The role of extracellular matrix metalloproteinase inducer glycosylation in regulating matrix metalloproteinases in periodontitis

Yang

J of Periodontal Research

et al. 2018

“…CD147 is widely expressed on the cell surface of different cancer types [8]. CD147 has been demonstrated to facilitate the synthesis and secretion of matrix metalloproteinases (MMPs)[9].…”

Section: Introductionmentioning

confidence: 99%

Elevated CD147 expression is associated with shorter overall survival in non-small cell lung cancer

et al. 2017

A number of studies have reported on the prognostic role of CD147 expression in non-small cell lung cancer (NSCLC); however, the results remain controversial. This study aims to investigate the impact of CD147 on the prognosis of NSCLC by means of a meta-analysis. A literature search was performed for relevant studies published before October 29, 2016. The hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated as effective measures. Sensitivity analysis and publication bias examination were also conducted. Ten eligible studies with a total of 1605 patients were included in this meta-analysis. CD147 overexpression was correlated with poor overall survival (OS) (HR=1.59, 95% CI=1.32–1.91, p<0.001). Elevated CD147 expression was associated with the presence of lymph node metastasis (OR=2.31, 95% CI=1.74–3.07, p<0.001) and advanced TNM stage (OR=3.03, 95% CI=1.24–7.39, p=0.015). However, no significant association between CD147 and sex, age, differentiation, or histology was found. No evidence of significant publication bias was identified. This meta-analysis revealed that overexpression of CD147 was associated with shorter OS, the presence of lymph node metastasis and advanced TNM stage in NSCLC. Therefore, CD147 could serve as a potential prognostic marker for NSCLC.

Molecular Carcinogenesis

“…24 As previously reported, CD147 is a tumor-associated antigen highly enriched on the surface of various malignant tumor cells, 25 and it is involved in the neoplastic cell behavior of tumors via CD147-mediated matrix metalloproteinase (MMP) production and interaction with various ligands. 26,27 As such, CD147 has also been suggested as an early diagnostic biomarker and a significantly unfavorable prognostic factor for various malignant tumors, 28 including NSCLC. 29 More importantly, CD147 has been demonstrated to promote glucose metabolism reprogramming in hepatocellular carcinoma.…”

mentioning

confidence: 99%

CD147‐mediated glucose metabolic regulation contributes to the predictive role of ¹⁸F‐FDG PET/CT imaging for EGFR‐TKI treatment sensitivity in NSCLC

Fu²,

Zhu³

et al. 2018

The aim of this study is to investigate the role of CD147 in glucose metabolic regulation and its association with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment sensitivity prediction using 18F‐fluorodeoxyglucose (18F‐FDG) PET/CT imaging in non‐small cell lung cancer (NSCLC). In this study, four human NSCLC cell lines with different EGFR‐TKI responses were used to detect p‐EGFR/EGFR and CD147 expression via Western blotting and flow cytometric analyses. Radioactive uptake of 18F‐FDG by established stable NSCLC cell lines (HCC827, H1975) with different levels of CD147 expression and the corresponding xenografts was assessed through γ‐radioimmunoassays in vitro and micro‐PET/CT imaging in vivo to study the role of CD147 in glucose metabolic reprogramming. Correlation analyses were performed to investigate the association between CD147 expression and PD‐L1 expression in stable NSCLC cell lines. Higher CD147 expression was found in EGFR‐TKI‐sensitive NSCLC cell lines than in relatively resistant NSCLC cell lines (HCC827>PC9>A549>H1975). CD147 could promote 18F‐FDG uptake by HCC827 and H1975 cells in vitro and in vivo through an EGFR‐initiated Akt/mTOR‐dependent signaling pathway. Programmed cell death‐ligand 1 (PD‐L1) expression was positively correlated with CD147 expression in human NSCLC cell lines. EGFR‐TKI treatment sensitivity prediction in NSCLC using 18F‐FDG PET/CT imaging significantly correlated with CD147‐mediated glucose metabolic regulation via the Akt/mTOR‐dependent pathway. Moreover, PD‐L1 expression in NSCLC cell lines could be regulated by CD147, suggesting a potential immunosuppression induced by the upregulation of tumor glucose metabolism.